Insomnia News and Research

Latest Insomnia News and Research

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Somaxon Pharmaceuticals, Inc. and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa.

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

7 Jun 2011

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 ADVANCE-PD and APEX-PD Phase III clinical study data will be presented in Poster Sessions at the 15th International Congress of Parkinson's Disease and Movement Disorders Conference in Toronto, Canada, held from June 5 to June 9.

4 Jun 2011

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon.

2 Jun 2011

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Two years ago, a widely publicized scientific report plucked an old mouse virus out of obscurity and held it up as a possible cause of Chronic Fatigue Syndrome. According to a new study published today by a group of researchers in California, Wisconsin and Illinois, that report was wrong.

1 Jun 2011

Chronic fatigue syndrome and mouse virus – no association

An earlier study published in 2009 had claimed that a mouse virus was the cause of chronic fatigue syndrome. New evidence suggests that this assumption is wrong. According to latest evidence the earlier study findings were likely based on contaminated lab samples, US researchers said Tuesday.

1 Jun 2011

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

New book on 'Overcoming Anxiety, Worry, and Fear'

Severe anxiety can leave its sufferers paralyzed with debilitating worry, uncontrollable fear and clinical depression. Although anxiety is the most common mental health problem in the U.S., many affected by anxiety don't know how to treat their problem or even how to seek help.

26 May 2011

Oral and injected steroids appear to be equally effective for sudden hearing loss

A relatively new treatment for sudden hearing loss that involves injecting steroids into the middle ear appears to work just as well as the current standard of oral steroids, a study by researchers at Johns Hopkins and other institutions suggests.

25 May 2011

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda Global Research & Development Center, Inc. U.S., today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone.

24 May 2011

Edurant receives FDA approval for treatment of HIV-1 infection

The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

21 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Tips to get better sleep

Your life is already tense — teens rebelling, house under renovation, work life in overload, bills piling up, elderly parents declining — yet the demands requiring your attention and time continue to grow, overflowing into sleep-time territory. Oftentimes, mass marketing's solutions to women's challenging lifestyles focus on quick fixes and more consumer goods.

18 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that the Company's Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.

10 May 2011

PTSD occurs with significant frequency in civilian patients after traumatic event involving physical injury

Although most commonly associated with military combat, post-traumatic stress disorder (PTSD) can occur in civilians, too - and with consequences that are just as serious, according to a new review article in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS). PTSD is a type of anxiety disorder that occurs after a person experiences a traumatic event involving physical injury, and occurs in 20 to 51 percent of patients with an orthopaedic injury.

9 May 2011

Insomnia News and Research

Latest Insomnia News and Research

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Millennium reports results from two VELCADE based combination studies against multiple myeloma

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Chronic fatigue syndrome and mouse virus – no association

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

New book on 'Overcoming Anxiety, Worry, and Fear'

Oral and injected steroids appear to be equally effective for sudden hearing loss

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Edurant receives FDA approval for treatment of HIV-1 infection

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Tips to get better sleep

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Naurex announces completion of $18 million Series A financing

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

PTSD occurs with significant frequency in civilian patients after traumatic event involving physical injury

Pharmaceutical Manufacturing - Industry Focus eBook eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Insomnia News and Research

Latest Insomnia News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in